Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is fi rmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs for lowering serum glucose, none to date have been shown to substantially reduce CV risk and some have been associated with adverse effects. Recent trials have examined the CV effects of the dipeptidyl peptidase 4 (DPP-4) inhibitors or "gliptins." antihyperglycemic drugs has provided an opportunity to determine the relative CV risk associated with these drugs. With this in mind, the FDA issued a 2008 guidance that manufacturers of new diabetes drugs should conduct studies to evaluate CV safety. 6 The newest class of glucose-lowering drugs to undertake this assessment of CV risk is the dipeptidyl peptidase 4 (DPP-4) inhibitors. This article will discuss the fi ndings from 2 recent clinical trials assessing the CV risk of these agents and the ongoing issues related to preventing macrovascular complications in patients with diabetes.
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DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS
DPP-4 inhibitors, commonly referred to as "gliptins," block the degradation of incretin hormones that are involved in the regulation of glucose and insulin. 7 The DPP-4 inhibitors were introduced in 2006. Due to their high cost, DPP-4 inhibitors are generally reserved for add-on therapy in patients who have not achieved adequate glycemic control with other drugs. Initial small studies suggested that DPP-4 inhibitors may have benefi cial effects on the CV system. Increases in left ventricular contractility in patients with ischemic heart disease as well as reductions in blood pressure and postprandial lipid levels have been reported. 7 In a subsequent meta-analysis of 70 trials involving almost 42,000 patients and 44 weeks of follow-up, DPP-4 T ype 2 diabetes affects an estimated 25.8 million individuals in the United States. 1 Almost 2 million new cases were diagnosed in 2010 among adults 20 years of age and older. Data from the US Health and Nutritional Examination Survey (NHANES) indicate that the prevalence of diabetes increased dramatically from an estimated 6.2% for 1988-1994 to an estimated 9.9% for 2005-2010. 2 Diabetes is associated with accelerated atherosclerosis and is often considered to be a "coronary equivalent." The overall risks of cardiovascular disease (CVD) and stroke are 2 to 4 times higher in individuals with diabetes compared to nondiabetics. 1 Despite the availability of numerous therapeutic agents with proven effi cacy for lowering blood glucose, none have been shown to substantially reduce CV risk. Even more concerning is the fact that a number of these drugs have been associated with detrimental effects. For example, thiazolidinediones including rosiglitazone and pioglitazone, have been associated with an increased risk of heart failure resulting in a black box warning. 3 Rosiglitazone has previously been associated with a potential increased risk of myocardial infarction and, although many of the restrictions on its use have now been removed, the US Food and Drug Administration (FDA) continues to monitor. 4, 5 Because CVD is a leading cause of death among diabetics, the development of additional Volume 49, September 2014 inhibitors were associated with reductions in major adverse CV events (odds ratio [OR], 0.71; 95% CI, 0.59-0.86; P < .001). 8 A separate pooled analyses of data from the saxagliptin phase 2b-3 development program involving 4,607 patients showed lower rates of the combined endpoint of CV death/myocardial infarction/stroke (relative risk [RR], 0.43; 95% CI, 0.23-0.80). 9 In response to the FDA's guidance, 2 randomized placebo controlled trials evaluating CV risk were conducted, and the fi ndings were reported at the European Society of Cardiology 2013 annual meeting. 10, 11 
CLINICAL TRIALS OF CARDIOVASCULAR RISK WITH DPP-4 INHIBITORS
The fi rst study, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI 53) trial, included 16,492 patients with type 2 diabetes, a glycated hemoglobin (A1C) of 6.5% to 12%, and either a history of CVD or multiple risk factors. 10 The study population had a mean age of 65 years and a median diabetes duration of 10 years. Saxagliptin was initiated at 5 mg daily or 2.5 mg for those with a glomerular fi ltration rate less than or equal to 50 mL/min. Physicians were allowed to adjust other medications, including antihyperglycemic agents, as needed. The primary endpoint was a composite of CV death, myocardial infarction, or ischemic stroke. After a median followup of 2.1 years, the primary endpoint occurred in 7.3% of saxagliptin versus 7.2% on placebo groups (hazard ratio [HR], 1.00; 95% CI, 0.89-1.12; P = .99 for superiority; P < .001 for noninferiority). Unexpectedly, saxagliptin patients were found to be at increased risk for hospitalization due to heart failure (3.5% vs 2.8%; P = .007). The mean A1C was 0.2% lower in the saxagliptin group compared to placebo (P < .001) and hypoglycemia occurred more frequently with saxagliptin (15.3% vs 13.4%; P < .001).
The SAVOR-TIMI 53 investigators offered 3 possible explanations for the observed lack of CV benefi t. First, the study duration may have been too short to positively impact CV outcomes. Second, the difference in A1C levels was relatively small throughout the trial. The investigators attributed this to the fact that although baseline use of nonstudy glucoselowering drugs was similar between the groups, the use of insulin increased by approximately 5% in the placebo arm during the trial. Third, the overall event rates were relatively low, perhaps due to the widespread use of other cardioprotective drugs, thus making it more diffi cult to demonstrate signifi cant differences. Reasons for the increase in heart failure hospitalizations were not clear.
The second study was the Examination of Cardiovascular Outcomes with Alogliptin vs Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE) trial. 11 This trial randomized 5,380 diabetic patients who were hospitalized for an acute coronary syndrome within the previous 15 to 90 days and had a baseline A1C of 6.5% to 11%. Patients were initiated on alogliptin 25 mg daily or placebo. Doses were modifi ed for those with glomerular fi ltration rates below 60 mL/min. Additional antihyperglycemic and CV drugs were allowed as needed. Follow-up was conducted for a median of 18 months. The primary endpoint of death from CV causes, nonfatal myocardial infarction, or nonfatal stroke occurred in 11.3% of patients assigned to alogliptin compared to 11.8% of placebo patients (P < .001 for noninferiority and P = .32 for superiority). Alogliptin lowered A1C by an additional 0.3% and was not associated with increased hypoglycemia compared to placebo.
The EXAMINE investigators also commented that a longer duration trial may have been needed to demonstrate benefi t. Reductions in A1C were small in this trial and similar to those seen in SAVOR-TIMI 53. Although the use of other antihyperglycemic drugs was matched at baseline, changes in the use of these agents by the end of the study were not reported.
DISCUSSION
Even though SAVOR-TIMI 53 and EXAMINE provide evidence that saxagliptin and alogliptin do not adversely affect CV endpoints such as myocardial infarction and stroke, the lack of any positive impact is disappointing. As is true for all studies, the design limitations must be taken into account when interpreting the fi ndings. Along with the relatively small reductions in A1C achieved in these trials, the lack of control over the use of nonstudy antihyperglycemic drugs is a potential confounder. Additionally, the trials were adequately powered and included over 20,000 patients, but the vast majority of the patients were White. Further studies are needed that include Black and Hispanic patients, 2 groups with even higher CV risks. The fi nding of increased heart failure hospitalizations with saxagliptin in SAVOR-TIMI 53 raises a cautionary fl ag that must be further examined. Unfortunately, heart failure hospitalizations have not been included as a predefi ned endpoint in any other gliptin studies. A recent meta-analysis pooled data from 84 studies to examine the relationship between DPP-4 inhibitors therapy and heart failure. 12 The overall risk of acute heart failure was found to be higher with DPP-4 inhibitor therapy (OR, 1.19; 95% CI, 1.03-1.37; P = .015). The increased risk appeared to be a class effect as no differences were seen among the various DPP-4 inhibitors included in the analysis. In response to this concern, the FDA is currently conducting an analysis of the risk of heart failure associated with saxagliptin. 13 Finally, although these 2 clinical trials were specifi cally designed to address the issue of CV risk, it is disappointing that microvascular outcomes were not included in the endpoints. Given the relatively small reductions in blood glucose levels achieved in both trials, one cannot assume that benefi ts would have occurred.
Glycemic Control as a Surrogate for Vascular Disease
Treatment goals for patients with diabetes focus on controlling blood glucose levels, which will in turn reduce target organ damage. Diabetes is associated with microvascular damage in the eyes, kidneys, and nerves as well as macrovascular damage involving the heart and brain. The link between elevated serum glucose and end organ damage is well established. 14 The mechanisms through which hyperglycemia mediates vascular damage are complex and multifactorial, including formation of advanced glycation end products and increased release of proinfl ammatory molecules, as well as impaired endothelial, fi brinolytic, and platelet function. 15 Numerous studies have demonstrated a link between glycemic control and reductions in microvascular damage. In type I diabetics, there is conclusive evidence from the Diabetes Control and Complications Trial (DCCC) that intensive glucose control reduces microvascular complications such as retinopathy, nephropathy, and neuropathy. 16 No differences were seen in macrovascular complications during the initial trial. However, for the 93% of trial participants who were then followed for a mean of 17 years in the Epidemiology of Diabetes Interventions and Complications (EPIC) Study, intensive glucose control was associated with a reduction in CV events (RR, 42%; 95% CI, 9%-63%; P = .02). 17 These fi ndings support the hypothesis that longer treatment durations may be needed to signifi cantly affect CV endpoints.
An observational study in type 2 diabetes, the United Kingdom Prospective Diabetes Study UKPDS, demonstrated the association between hyperglycemia and both microvascular and macrovascular complications. 18 This study enrolled 4,209 diabetic individuals soon after their diagnosis and followed them for a median of 10 years. Various drugs including metformin, sulfonylureas, and insulin were utilized. Each 1% reduction in A1C was associated with a 21% risk reduction for any endpoint related to diabetes (95% CI, 17%-24%; P < .0001), a 21% reduction for deaths related to diabetes (95% CI, 15%-27%; P < .0001), and a 14% reduction for myocardial infarction (95% CI, 8%-21%; P < .0001). The risk reduction in microvascular complications was even greater (RR, 37%; 95% CI, 33%-41%; P < .0001).
In an effort to more fully determine the effectiveness of intensive glucose lowering on macrovascular complications, 3 clinical trials have been conducted. [19] [20] [21] The Action to Control Cardiovascular Risk in Diabetes (ACCORD) was a randomized trial of 10,251 patients with a median A1C of 8.1%. 19 Patients were assigned to intensive therapy with a target A1C of less than 6.0% or standard therapy with a target A1C of 7.0% to 7.9%. Treatments included various combinations of insulin, metformin, sulfonylureas, and thiazolinediones. At 1 year, stable median A1C levels of 6.4% and 7.5% were achieved in the intensive and standard therapy groups, respectively. After a mean follow-up of 3.5 years, the primary outcome, a composite of nonfatal myocardial infarction, nonfatal stroke, or death from CV causes, was not signifi cantly different between groups (HR, 0.90; 95% CI, 0.78-1.04; P = .16). Particularly concerning was the fi nding that mortality was higher in the intensive therapy group (HR, 1.22; 95% CI, 1.01-1.46; P = .04), leading to early termination of the trial.
A second trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modifi ed Release Controlled Evaluation (ADVANCE), was a randomized, controlled, multicenter trial of 11,140 patients with type 2 diabetes that compared standard glucose control to intensive glucose control (defi ned as a A1C of 6.5% or less). 20 The intensive control group received gliclazide, a sulfonylurea not available in the United States, plus additional therapy as directed by their physician. The primary endpoint was a composite of macrovascular and microvascular events. After a median follow-up of 5 years, the mean A1C in the intensive control group was 6.5% compared to 7.3% in the standard control group. The combined incidence of macrovascular and microvascular events was 18.1% in the intensive control group Volume 49, September 2014 versus 20.0% in the standard control group (HR, 0.90; 95% CI, 0.82-0.98; P = .01). This risk reduction, however, was due primarily to a 21% decrease in new or worsening nephropathy. When analyzed separately, intensive control was associated with a reduced risk of microvascular events (HR, 0.86; 95% CI, 0.77-0.97, P = .01) but no difference in the risk of macrovascular events (HR, 0.94; 95% CI, 0.84-1.06; P = .32).
The third trial, the Veterans Affairs Diabetes Trial (VADT), randomized 1,791 military veterans with type 2 diabetes and a mean baseline A1C of 9.4%. 21 The mean age of participants was 60.4 years, and the mean number of years since the diagnosis of diabetes was 11.5. Patients were randomized to either intensive therapy with a goal of reducing the A1C by 1.5% or standard therapy. The primary outcome was the fi rst occurrence of any composite of CV events. The median A1C stabilized after 6 months at 6.9% in the intensive therapy group versus 8.4% in the standard therapy group. However, after a median follow-up of 5.6 years, there was no reduction in the primary endpoint (OR, 0.88; 95% CI, 0.74-1.05; P = .14).
Along with the fi ndings from these 3 trials, SAVOR-TIMI 53 and EXAMINE raise further questions about the utility of glycemic control as a surrogate for macrovascular damage. Moreover, the trial fi ndings suggest that the duration of diabetes, baseline presence of CV risk factors or disease, and length of follow-up are all important factors that must be taken into account when assessing a drug's effectiveness for preventing CV complications.
Evidence from ACCORD, ADVANCE, and VADT suggest that patients with more advanced diabetes and a higher prevalence of prior macrovascular disease do not derive benefi t from intensive glucose control at least over 5 years of follow-up and that mortality may potentially be increased. Hypoglycemia that occurred frequently in ACCORD and VADT was a risk factor for CV complications. Conversely, based on the fi ndings from UKPDS, newly diagnosed diabetics and those without prior CVD may derive greater long-term benefi t from intensive glycemic control, assuming hypoglycemia can be minimized. These factors are refl ected in the most recent guidelines from the American Diabetes Association that recommend a target A1C for most patients of less than 7% but note a more stringent goal of less than 6.5% may be appropriate for newly diagnosed individuals with no history of microvascular or macrovascular disease and a more lenient goal of less than 8% may be more appropriate for those with advanced disease and more complications. 22 Lastly, it should be kept in mind that reducing hyperglycemia is only one factor that must be considered in reducing a patient's overall risk for CV disease or stroke. This was demonstrated in the Steno-2 study that involved long-term interventions targeted to reduce A1C, blood pressure, cholesterol, triglycerides, and urinary albumin excretion based on national guidelines. 23 The A1C goal was less than 6.5% using diet, exercise, and various older drugs including metformin, sulfonylureas, and insulin as needed. The study randomized 160 patients who had mean age 55.1 years with type 2 diabetes and microalbuminuria. After a mean follow-up of 7.8 years, signifi cant reductions were seen in both macrovascular and microvascular endpoints: CVD (HR, 0.47; 95% CI, 0.24-0.73), nephropathy (HR, 0.39; 95% CI, 0.17-0.87), retinopathy (HR, 0.42; 95% CI, 0.21-0.86), and autonomic neuropathy (HR, 0.37; 95% CI, 0.18-0.79). This study provides evidence that a comprehensive program targeting lifestyle changes and risk factor modifi cation will likely be the most effective approach for preventing long-term complications.
Conclusions
Diabetes is a rapidly escalating public health problem. In 2012, the total costs of diagnosed diabetes were estimated at $245 billion. 24 CVD is a major contributor to morbidity and mortality in patients with type 2 diabetes. Additional clinical trials assessing the CV impact of newer drugs such as the DPP-4 inhibitors are ongoing and should be completed by 2017. However, the evidence to date for the DPP-4 inhibitors as well as other antihyperglycemic drugs has been disappointing. For patients with no prior history of CV disease, intensive glucose-lowering therapy soon after diagnosis may be effective, if frequent hypoglycemia can be avoided. For patients with more advanced disease and multiple comorbidities, no single intervention is enough. Rather, a multifaceted strategy should be implemented that targets blood glucose, blood pressure, serum lipids, and other CV risk factors. Less stringent glycemic goals may be appropriate for many of these patients. Frequent or severe hypoglycemia is an indication that treatment regimens should be modifi ed. Although the lack of CV benefi t in the recent DPP-4 inhibitor trials was disappointing, the absence of adverse effects on vascular disease is reassuring and the possibility of benefi t with longer duration follow-up has not been fully explored. Caution is advised, however, for patients at risk or with a history of heart failure until this issue can be further assessed. Overall, given the relatively high costs of the DPP-4 inhibitors, the lack of CV benefi t will likely keep these agents as add-on therapy. Pharmacists should bear in mind that many individuals with diabetes remain undiagnosed until complications appear. Thus ongoing efforts for early detection and education are also needed.
